Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company shows strong revenue growth and improved profitability, yet faces challenges with high marketing expenses and reliance on skincare. Despite an optimistic guidance, the Q&A reveals no new partnerships or groundbreaking strategies. With no market cap data, the impact is uncertain, but the mixed signals and existing risks suggest a neutral stock price movement.
Total Net Revenue (Q4 2025) RMB 1.38 billion, a 20.1% increase year-over-year. This growth was primarily driven by a 51.9% increase in net revenues from Skincare brands, partially offset by a 9.1% decrease in net revenues from Color Cosmetics brands.
Gross Profit (Q4 2025) RMB 1.07 billion, a 20% increase year-over-year. Gross margin remained largely flat at 77.7% compared to 77.8% in the prior year period.
Total Operating Expenses (Q4 2025) RMB 1.08 billion, a 15.6% decrease year-over-year. As a percentage of total net revenues, operating expenses decreased to 78.6% from 111.8% in the prior year period.
Fulfillment Expenses (Q4 2025) RMB 77 million, up from RMB 63.5 million in the prior year period. As a percentage of total net revenues, fulfillment expenses remained largely flat at 5.6% compared to 5.5%.
Selling and Marketing Expenses (Q4 2025) RMB 893.8 million, up from RMB 690.6 million in the prior year period. As a percentage of total net revenue, these expenses increased to 64.8% from 60.1%, driven by higher traffic acquisition costs during the Double 11 shopping festival.
General and Administrative Expenses (Q4 2025) RMB 74.4 million, down from RMB 100.1 million in the prior year period. As a percentage of total net revenues, these expenses decreased to 5.4% from 8.7%, primarily due to lower payroll and share-based compensation expenses.
Research and Development Expenses (Q4 2025) RMB 38.8 million, up from RMB 26.3 million in the prior year period. As a percentage of total net revenues, these expenses increased to 2.8% from 2.3%, driven by higher payroll expenses due to increased R&D headcount.
Net Income (Q4 2025) RMB 3 million, compared to a net loss of RMB 378.8 million in the prior year period. Net income margin was 0.2%, compared to a net loss margin of 33%.
Non-GAAP Net Income (Q4 2025) RMB 41.2 million, compared to RMB 107 million in the prior year period. Non-GAAP net income margin was 3%, compared to 9.3%.
Total Net Revenue (Full Year 2025) RMB 4.3 billion, a 26.7% increase year-over-year. This growth was driven by a 63.5% increase in net revenues from Skincare brands and a 1.9% increase in net revenues from Color Cosmetics brands.
Gross Profit (Full Year 2025) RMB 3.36 billion, a 28.4% increase year-over-year. Gross margin increased to 78.2% from 77.1%, driven by higher sales of higher-gross margin products.
Operating Loss (Full Year 2025) RMB 185.8 million, compared to RMB 824.9 million in the prior year period. Operating loss margin decreased to 4.3% from 24.3%, primarily due to the absence of goodwill impairment in 2025.
Net Loss (Full Year 2025) RMB 92.4 million, compared to RMB 710.2 million in the prior year period. Net loss margin decreased to 2.2% from 20.9%.
Non-GAAP Net Income (Full Year 2025) RMB 8.4 million, compared to a non-GAAP net loss of RMB 128.2 million in the prior year period. Non-GAAP net income margin was 0.2%, compared to a non-GAAP net loss margin of 3.8%.
R&D-led product innovation: Leveraged R&D infrastructure for innovative products, including AI applications in molecular structure prediction. Galenic launched VB serum and Couture Revelation Cellulaire reviving cream, both achieving significant market success.
Market positioning: Strengthened brand equities across a multi-brand portfolio, addressing diverse consumer needs. Dr. Wu launched PDRN serum, achieving robust growth and recognition as the annual growth breakthrough brand from Douyin.
Profitability improvement: Enhanced gross margin, optimized operational efficiencies, and achieved positive operating leverage. Full-year net loss margin reduced to 2.2% from 20.9%, with a non-GAAP net income margin of 0.2%.
Cost optimization: Optimized product mix for higher gross margins, improved marketing efficiencies, and streamlined operational workflows.
Strategic transformation: Focused on R&D innovation, brand equity strengthening, and profitability improvement. Achieved a 26.7% revenue growth year-over-year, driven by Skincare brands contributing 53% of total net revenues.
Intensified Competition: The beauty industry in China is experiencing intensified competition, particularly during major shopping festivals, which has led to higher traffic acquisition costs and increased selling and marketing expenses.
Decreased Revenue from Color Cosmetics: Net revenues from Color Cosmetics brands decreased by 9.1% year-over-year in Q4 2025, indicating challenges in this segment despite overall revenue growth.
High Selling and Marketing Expenses: Selling and marketing expenses increased to 64.8% of total net revenue in Q4 2025, driven by higher traffic acquisition costs, which could pressure profitability.
Cash Flow Challenges: Net cash used in operating activities for the full year of 2025 was RMB 94.7 million, indicating potential liquidity concerns despite profitability improvements.
Dependence on Skincare Brands: Skincare brands accounted for 61.1% of total net revenues in Q4 2025, showing a heavy reliance on this segment, which could pose risks if market dynamics shift.
Economic Uncertainties: The company acknowledges risks and uncertainties beyond its control that could materially affect its performance, as stated in the forward-looking statements disclaimer.
Business Outlook for Q1 2026: The company expects total net revenues to be between RMB 958.6 million and RMB 1.08 billion, representing a year-over-year increase of approximately 15% to 30%. These forecasts are based on current and preliminary views on market and operational conditions, which are subject to change.
The selected topic was not discussed during the call.
The company shows strong revenue growth and improved profitability, yet faces challenges with high marketing expenses and reliance on skincare. Despite an optimistic guidance, the Q&A reveals no new partnerships or groundbreaking strategies. With no market cap data, the impact is uncertain, but the mixed signals and existing risks suggest a neutral stock price movement.
The earnings call highlights strong financial performance, with significant revenue and gross profit growth, improved margins, and reduced losses. The Q&A section reveals optimism about profitability in Q4 and sustained growth through R&D and marketing optimization. Despite competition, the company's strategy to focus on high-end brands and innovation is promising. The lack of detailed guidance on expenses is a minor concern, but overall, the positive financial results and optimistic outlook suggest a positive stock price movement.
The earnings call reveals strong financial performance with increased gross margin, reduced operating losses, and a shift to non-GAAP net income. The strategic focus on high-margin skincare and R&D investments, alongside a share repurchase program, indicates confidence in future growth. Positive Q3 guidance for skincare and improved profitability strategies further bolster the outlook. Despite increased competition, the company's robust R&D capabilities and strategic initiatives suggest a positive trajectory. The Q&A section supports this with no significant concerns raised by analysts, reinforcing the positive sentiment.
The earnings call presents a mixed picture. Financial performance shows improvement, with increased net revenues, gross profit, and reduced losses, yet color cosmetics face a decline, reflecting market challenges. Regulatory and supply chain issues persist, and management's responses lacked clarity, especially regarding product promotion and sales forecasts. The share repurchase program is a positive, but the absence of concrete guidance tempers optimism. Overall, the sentiment is neutral, as the positives are balanced by ongoing challenges and uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.